‘ColoPrint’s definitive results will enable doctors to choose treatment plans for colon cancer sufferers that are customized for each patient’s individual needs,’ stated David Macdonald, Agendia CEO. ‘We anticipate ColoPrint to end up being well received amongst doctors and patients for a more personalized management of the disease.’.. Agendia launches ColoPrint microarray-based 18-gene expression signature for colon cancer Agendia, a forward thinking molecular cancer diagnostics leader and firm in personalized medicine, today announced the launch of its ColoPrint microarray-based 18-gene expression signature for predicting the risk of distant recurrence for stage II cancer of the colon patients who have undergone surgery.Robert Lanza MD, and its own collaborators. The paper reviews that iPS cells exhibit irregular expansion and early cellular ageing, raising important questions about the future leads for iPS cell-structured therapies and helping the use of ACT’s embryo-safe one blastomere-derived human embryonic stem cell lines, which do not exhibit these problems. Caldwell, IV, Chairman and CEO of Advanced Cell. We believe this study further validates the need to commercialize our blastomere technology, which continues to be on plan to begin with clinical trials in humans through the 2010 third quarter.. Paul J. Newey, D.Phil., Caroline M. Gorvin, D.Phil., Stephen J. Cleland, Ph.D., Christian B. Willberg, D.Phil., Marcus Bridge, B.Sc., Mohammed Azharuddin, M.B., B.S., Russell S.